TAK-285 Size:Solid 10 mg which directly correlated with the

which directly correlated with the observed inhibition of transport activity

31)28-13-12-17(15-28)6-11-23(29)26-22-5-3-2-4-21(22)24/h2-16H

an Effective Constituent of Ligustrum lucidum Ait

CAS Number: 226700-81-8

Smiles: CC(N[C@@H]1C[C@H]1C1C=CC=CC=1)C1=CC2OCCOC=2C=C1

TAK-285 Size:Solid 10 mg which directly correlated with theTAK 285 is a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor receptor (EGFR) and HER2. Methods: TAK 285 is currently being developed by Takeda. TAK 285 was found to be well tolerate in Phase I trials. Absorption of TAK 285 was rapid after oral dosing, and plasma exposure at steady state increased in a dose proportional fashion for doses ranging from 50 to 300 mg b. i. d. A partial response was observed